Jim Cramer sees signs everywhere that the worst is over for pharma. » Read More
NEW YORK _ Bristol-Myers Squibb Co. on Thursday reported first-quarter earnings of $1.2 billion. The average estimate of 10 analysts surveyed by Zacks Investment Research was for earnings of 66 cents per share. Seven analysts surveyed by Zacks expected $4.24 billion.
TRENTON, N.J.— Bristol-Myers Squibb Co. trounced Wall Street's first-quarter profit expectations as soaring sales of key new medicines offset higher expenses and a big hit from generic competition. The New York- based company said Thursday that its net income amounted to $1.2 billion, up 0.8 percent from $1.19 billion in 2015' s first-quarter.
Some 30 American companies were recognized for their efforts to boost diversity and inclusion.
It's the busiest earnings week of the quarter. The HR experts give a preview
Jim Cramer provides his opinion on how to diversify various investor portfolios, including the great FB vs AAPL conundrum.
Jim Cramer details how Washington has set out to stop the American investor.
Jim Cramer rattles off his take on caller favorite stocks, including this popular pharmaceutical stock that has Cramer as a buyer.
Mad Money host Jim Cramer believes presidential politics will have no impact on this high-profile stock.
"Halftime Report" trader Pete Najarian bought shares of a pharma giant on Wednesday after spotting unusual options activity.
Jim Cramer admitted he was totally wrong about this stock. He is now a believer, and thinks you should be, too.
The FMHR traders take their positions on four stocks making news today, including Bristol-Myers moving higher after Barron's said the stock could rise 25 percent in 2016.
U.S. stock index futures indicated a mixed open Thursday after December durable goods orders declined far more than expected.
Earnings forecast may be dim, but these five stocks are winners, says Goldman Sachs' David Kostin.
Biotech stocks endured a rough Monday, and struggles may continue throughout the year for the high-growth sector, one trader said.
Jan 7- Dynavax Technologies Corp said its experimental hepatitis B vaccine was found to be safe and effective in a late-stage study, paving the way for the company to resubmit its marketing application. The earlier marketing application for the vaccine, HEPLISAV-B, was rejected in February 2013 by the U.S. Food and Drug Administration, which sought additional...
Jim Cramer prepares investors with his shopping list of stocks to avoid and buy amid the worldwide sell-off.
The "Fast Money" traders give their final trades for 2015.
NEW YORK, Dec 23- A new class of blood thinners that competes with widely used warfarin should get a boost next year when an "antidote" that can reverse the medications' effects in an emergency is expected to enter the market, according to top U.S. heart doctors and investors. Xarelto, from Bayer AG and Johnson& Johnson, and Eliquis, sold by Bristol-Myers Squibb and...
Jim Cramer rattles off his take on caller favorite stocks, including this play on commodities.
Some of the names on the move ahead of the open.